China NMPA Drug Inspection - Yueyang Tianxiang Traditional Chinese Medicine Pieces Co., Ltd. - safflower

On November 28, 2017, the Henan Provincial Food and Drug Administration, operating under China's National Medical Products Administration (NMPA) framework, issued an announcement detailing findings from drug inspections. This regulatory action identified four batches of drugs from four different companies as substandard following testing by various provincial drug inspection agencies.The companies and their respective violations included: Yuzhou Baicaohui Pharmaceutical Co., Ltd., whose Agarwood (batch 160522) was found to be substandard; Yuzhou Jindi Traditional Chinese Medicine Pieces Co., Ltd., where Mulberry Mistletoe (batch 151101) failed quality due to appearance issues; Luoyang Kangxin Traditional Chinese Medicine Pieces Co., Ltd., with Safflower (batch 170101) being substandard due to excessive acid-insoluble ash content; and Henan Shennong Pharmaceutical Co., Ltd., whose Qingkailing Injection (batch 16100201) contained visible foreign matter.In response to these quality deficiencies, the Henan Provincial Food and Drug Administration mandated immediate risk control measures. These included the sealing, seizure, and suspension of sales for all identified substandard drug batches. Furthermore, the regulatory body directed its departments to conduct thorough investigations and impose legal penalties on the entities responsible for distributing or sourcing these non-compliant products, underscoring a commitment to upholding pharmaceutical quality and safety standards within the region.